Ta1722, an anti-angiogenesis inhibitor targeted on VEGFR-2 against human hepatoma

Biomedicine and Pharmacotherapy

Volumn 66, Issue 7, 2012, Pages 499-505

  Zheng, Lei ^a   He, Xu ^a   Ma, Weina ^a   Dai, Bingling ^a   Zhan, Yingzhuan ^a   Zhang, Yanmin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Angiogenesis; Hepatoma; Ta1722; VEGFR 2

Indexed keywords

ANGIOGENESIS INHIBITOR; MESSENGER RNA; TA 1722; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN MCF 7; CHICK EMBRYO; CHORIOALLANTOIS; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ACETANILIDES; ANGIOGENESIS INHIBITORS; ANIMALS; BENZAMIDES; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DOWN-REGULATION; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867334812     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.05.002     Document Type: Article

References (37)

1. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
2. Risau W. Mechanisms of angiogenesis. Nature 1997, 386:671-674.
3. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9:653-660.
4. Folkman J., Bach M., Rowe J.W., Davidoff F., Lambert P., Hirsch C., et al. Tumor angiogenesis: therapeutic implications. New Engl J Med 1971, 285:1182-1186.
5. Yoshikawa D., Ojima H., Kokubu A., Ochiya T., Kasai S., Hirohashi S., et al. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signaling, as a novel molecular-targeted therapy against cholangiocarcinoma. Brit J Cancer 2009, 100:1257-1266.
6. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
7. Tan W.F., Lin L.P., Li M.H., Zhang Y.X., Tong Y.G., Xiao D., et al. Quercetin, a dietary-derived flavonoid, possesses antiangiogenic potential. Eur J Pharmacol 2003, 459:255-262.
8. Ribatti D., Nico B., Morbidelli L., Donnini S., Ziche M., Vacca A., et al. Cell-mediated delivery of fibroblast growth factor-2 and vascular endothelial growth factor onto the chick chorioallantoic membrane: endothelial fenestration and angiogenesis. J Vasc Res 2001, 38:389-397.
9. Brychtova S., Fiuraskova M., Malikova J., Sedlakova E., Bienova M., Kucerova R., et al. Angiogenesis in human cutaneous tumors. Eur J Cancer Suppl 2006, 4:32.
10. Fayette M., Soria J.C., Armand J.P. Use of angiogenesis inhibitors in tumour treatment. Eur J Cancer 2005, 41:1109-1116.
11. Eskens F.A.L.M., Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors. Eur J Cancer 2006, 42:3127-3129.
12. Matsumoto T., Mugishima H. Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. J Atheroscler Thromb 2006, 13:130-135.
13. Zhong H.Z., Bowen J.P. Molecular design and clinical development of VEGFR kinase inhibitors. Curr Top Med Chem 2007, 7:1379-1393.
14. Mazeron R., Bourhis J., Deutsch E. Angiogenesis inhibitors and radiation therapy: concept and preliminary results. Bull Cancer 2009, 96:299-310.
15. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 2006, 312:594-607.
16. Zhang J., Zhang Y.M., Zhang S.Q., Wang S.C., He L.C. Discovery of novel taspine derivatives as antiangiogenic agents. Bioorg Med Chem Lett 2010, 20:718-721.
17. Li Y.P., He L.C. Establishment of the model of vascular endothelial cell membrane chromatography and its preliminary application. Chin Sci Bull 2007, 52:922-928.
18. Perdue G.P., Blomster R.N., Blake D.A., Farnsworth N.R. South American plants II: taspine isolation and anti-inflammatory activity. J Pharm Sci 1979, 68:124-126.
19. Rollinger J.M., Schuster D., Baier E., Ellmerer E.P., Langer T., Stuppner H., et al. Bioactivity-guided isolation and molecular ligand-target insight of a potent acetylcholinesterase inhibitor from Magnolia x soulangiana. J Nat Prod 2006, 69:1341-1346.
20. Porras-Reyes B.H., Lewis W.H., Roman J., Simchowitz L., Mustoe T.A. Enhancement of wound healing by the alkaloid taspine defining mechanism of action. Proc Soc Exp Biol Med 1993, 203:18-25.
21. Itokawa H., Ichihara Y., Mochizuki M., Enomori T., Morita H., Shirota O., et al. A cytotoxic substance from Sangre de Grado. Chem Pharm Bull 1991, 39:1041-1042.
22. Pieters L., Debruyne T., Claeys M., Vlietinck A., Calomme M., Vandenberghe D. Isolation of a dihydrobenzofuran lignan from South American dragon's blood (Croton spp.) as an inhibitor of cell proliferation. J Nat Prod 1993, 56:899-906.
23. Zhang Y.M., He L.C., Meng L., Luo W.J., Xu X.M. Suppression of tumor-induced angiogenesis by taspine isolated from Radix et Rhizoma Leonticis and its mechanism of action in vitro. Cancer Lett 2008, 262:103-113.
24. Zhao J., Zhao L., Chen W., He L.H., Li X. Taspine downregulates VEGF expression and inhibits proliferation of vascular endothelial cells through PI3 kinase and MAP kinase signaling pathways. Biomed Pharmacother 2008, 62:383-389.
25. Zhang Y.M., Zhang J., Dai B.L., Wang N., He L.C. Anti-proliferative and apoptotic effects of the novel taspine derivative tas41 in the Caco-2 cell line. Environ Toxicol Pharmacol 2011, 31:406-415.
26. Cai Y.C., Zou Y., Ye Y.L., Sun H.Y., Su Q.G., Wang Z.X., et al. Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium (M410). Invest New Drug 2011, 29:300-311.
27. Zhang J., Zhang Y.M., Pan X.Y., Wang S.C., He L.C. Synthesis and cytotoxic evaluation of novel symmetrical taspine derivatives as anticancer agents. Med Chem 2011, 7:286-294.
28. Naruse I., Ohmori T., Ao Y., Fukumoto H., Kuroki T., Mori M. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 2002, 98:310-315.
29. Liao C.H., Guh J.H., Chueh S.C., Yu H.J. Anti-angiogenic effects and mechanism of prazosin. Prostate 2011, 71:976-984.
30. Toi M., Bando H., Ramachandran C., Melnick S.J., Imai A., Fife R.S., et al. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Angiogenesis 2003, 6:121-128.
31. Seidlitz E., Korbie D., Marien L., Richardson M., Singh G. Quantification of anti-angiogenesis using the capillaries of the chick chorioallantoic membrane demonstrates that the effect of human angiostatin is age-dependent. Microvasc Res 2004, 67:105-116.
32. Zhang Y.M., Zheng L., Zhang J., Dai B.L., Wang N., Chen Y.N., et al. Antitumor activity of taspine by modulating the EGFR signaling pathway of Erk1/2 and Akt in vitro and in vivo. Planta Med 2011, 77:1774-1781.
33. Shimamura M., Hazato T., Ashino H., Yamamoto Y., Iwasaki E., Tobe H., et al. Inhibition of angiogenesis by humulone, a bitter acid from beer hop. Biochem Bioph Res Co 2001, 289:220-224.
34. Takabatake D., Fujita T., Shien T., Kawasaki K., Taira N., Yoshitomi S., et al. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231). Int J Cancer 2006, 120:181-188.
35. Desbois-Mouthon C., Cacheux W., Blivet-van Eggelpoel M.J., Barbu V., Fartoux L., Poupon R., et al. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer 2006, 119:2557-2566.
36. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
37. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 2003, 31:1171-1177.